Multiple Immunofluorescence Imaging Analysis Reveals Differential Expression of Disialogangliosides GD3 and GD2 in Neuroblastomas

Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies

(2020) Dana L. Casey et al.   Cancer Immunology Research

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

(2020) Bassel Nazha et al.   Frontiers in Oncology

Neuroblastoma

(2018) Akira Nakagawara et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas

(2018) Christopher W. Mount et al.   NATURE MEDICINE

Differential roles of gangliosides in malignant properties of melanomas

(2018) Yuhsuke Ohmi et al.   PLoS One

Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers

(2018) Claudia Rossig et al.   Frontiers in Oncology

Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy

(2017) Tatjana Terzic et al.   PEDIATRIC AND DEVELOPMENTAL PATHOLOGY

Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults

(2016) Konstantin Dobrenkov et al.   PEDIATRIC BLOOD & CANCER

Ganglioside GD2 in reception and transduction of cell death signal in tumor cells

(2014) Igor I Doronin et al.   BMC CANCER

Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with β-Glucan for High-Risk Neuroblastoma in Second or Later Remission

(2014) Brian H. Kushner et al.   CLINICAL CANCER RESEARCH

GD3 synthase regulates epithelial–mesenchymal transition and metastasis in breast cancer

(2014) T R Sarkar et al.   ONCOGENE

Semi-Nested Real-Time Reverse Transcription Polymerase Chain Reaction Methods for the Successful Quantitation of Cytokeratin mRNA Expression Levels for the Subtyping of Non-Small-Cell Lung Carcinoma Using Paraffin-Embedded and Microdissected Lung Biopsy Specimens

(2013) Yoko Nakanishi et al.   ACTA HISTOCHEMICA ET CYTOCHEMICA

How Do Gangliosides Regulate RTKs Signaling?

(2013) Sylvain Julien et al.   Cells

Molecular Identification of GD3 as a Suppressor of the Innate Immune Response in Ovarian Cancer

(2012) T. J. Webb et al.   CANCER RESEARCH

Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3

(2012) Hidenobu Shibuya et al.   CANCER SCIENCE

Promising Therapeutic Targets in Neuroblastoma

(2012) K. K. Matthay et al.   CLINICAL CANCER RESEARCH

Functional Activation of Src Family Kinase Yes Protein Is Essential for the Enhanced Malignant Properties of Human Melanoma Cells Expressing Ganglioside GD3

(2011) Kazunori Hamamura et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting the GD3 acetylation pathway selectively induces apoptosis in glioblastoma

(2011) Suzanne M. Birks et al.   NEURO-ONCOLOGY

Shedding of GD2 ganglioside in patients with retinoblastoma

(2010) Jacques Portoukalian et al.   INTERNATIONAL JOURNAL OF CANCER

Ganglioside GD3 Enhances Adhesion Signals and Augments Malignant Properties of Melanoma Cells by Recruiting Integrins to Glycolipid-enriched Microdomains

(2010) Yuki Ohkawa et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

(2009) K Beiske et al.   BRITISH JOURNAL OF CANCER

Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study

(2009) Katherine K. Matthay et al.   JOURNAL OF CLINICAL ONCOLOGY

GD3 Synthase Overexpression Sensitizes Hepatocarcinoma Cells to Hypoxia and Reduces Tumor Growth by Suppressing the cSrc/NF-κB Survival Pathway

(2009) Josep M. Lluis et al.   PLoS One

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

(2008) Susan L. Cohn et al.   JOURNAL OF CLINICAL ONCOLOGY